Sorafenib is a multikinase inhibitor and refametinib is a MEK inhibitor; both of them, in combination, repressed Wnt/β-catenin signaling, inhibiting cell proliferation and promoting apoptosis in hepatocellular carcinoma (HCC) models (60). The gene discussed is MAP2K7; the disease is hepatocellular carcinoma.